Should we consider ezetimibe to reach even lower LDL-C targets?

Current Medical Research and Opinion

Volumn 31, Issue 3, 2015, Pages 459-460

  Agouridis, Aris P ^a,b   Mikhailidis, Dimitri P ^c  

^a UNIVERSITY OF IOANNINA   (Greece)

^b ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

CARDIOVASCULAR RISK; DRUG INDICATION; DYSLIPIDEMIA; HUMAN; ISCHEMIC HEART DISEASE; LETTER; COMPLICATION; CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; MALE; MEDICATION COMPLIANCE;

CORONARY DISEASE; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MEDICATION ADHERENCE;

EID: 84924598588     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1005204     Document Type: Letter

References (10)

1. Kern DM, Balu S, Tunceli O, et al. Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III. Curr Med Res Opin 2014;30:2443-51
2. Kohno T. Report of the American Heart Association (AHA) Scientific Sessions 2014, Chicago. Circ J 2014; in press
3. Stitziel NO, Won HH, Morrison AC, et al. Inactivating mutations in NPC1L1 and protection from coronary heart disease. N Engl J Med 2014;371: 2072-82
4. Katsiki N, Theocharidou E, Karagiannis A, et al. Ezetimibe therapy for dysli-pidemia: an update. Curr Pharm Des 2013;19:3107-14
5. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
6. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011;27:1191-210
7. Gudzune KA, Monroe AK, Sharma R, et al. Effectiveness of combination therapy with statin and another lipid-modifying agent compared with intensified statin monotherapy: a systematic review. Ann Intern Med 2014;160:468-76
8. Barkas F, Milionis H, Kostapanos MS, et al. How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic. Curr Med Res Opin 2014;1-8. [Epub ahead of print]
9. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63:2889-934
10. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dysli-pidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818